4 - XOMA Royalty Corp (0000791908) (Issuer)

4 - XOMA Royalty Corp (0000791908) (Issuer)

4 - XOMA Corp (0000791908) (Issuer)

4 - XOMA Corp (0000791908) (Issuer)

4 - XOMA Corp (0000791908) (Issuer)

4 - XOMA Corp (0000791908) (Issuer)

4 - XOMA Corp (0000791908) (Issuer)

4 - XOMA Corp (0000791908) (Issuer)

4 - XOMA Corp (0000791908) (Issuer)

4 - XOMA Corp (0000791908) (Issuer)

4 - XOMA Corp (0000791908) (Issuer)

4 - XOMA Corp (0000791908) (Issuer)

4 - XOMA Corp (0000791908) (Issuer)

Zevra's MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty's portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience's portfolio of 60-plus licensed early-stage assets across approximately 30 partners Cash receipts totaled $9.9 million in the third quarter, and $42.3 million for the first nine months of 2024 EMERYVILLE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, reported its third quarter 2024 financial results and highlighted recent activities. "We continue to take a balanced approach to building a portfolio of sustainable cashflow streams

XOMA Royalty has acquired 50 percent of Twist's existing royalty and milestone economics for $15 million XOMA Royalty's portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to pre-clinical programs EMERYVILLE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) announced today it has entered into a $15 million royalty monetization arrangement with Twist Bioscience Corporation to acquire a 50 percent economic interest in all future milestones and royalties associated with the 60-plus partnered early-stage programs across 30 partners enabled by Twist Bioscience's Biopharma Solutions business unit. "This transaction furth

Twist to retain all upfront, service and other revenue earned under antibody discovery and biopharma solutions agreements as well as half of future milestones and royalties Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a royalty purchase agreement with XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator. Under the terms of the agreement, XOMA Royalty will provide Twist Bioscience an upfront payment of $15 million in cash in exchange for the right to receive half of the future potential milestone and royalty payments res

MIPLYFFA™ is the first therapy approved for use in patients with NPC, a rare genetic disorder XOMA Royalty is entitled to receive a mid-single digit royalty on MIPLYFFA™ sales and up to $52.6 million in milestones MIPLYFFA™ is now the sixth commercial asset in XOMA Royalty's portfolio EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today Zevra Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for MIPLYFFA™ (arimoclomol).  MIPLYFFA™ is approved for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC)

 EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA" or the "Company") today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share.   Holders of depositary shares, each representing 1/1000 of a share of XOMA's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share.   The preferred dividends will be paid on or about Octo

EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following September 2024 investor conferences: H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024, in New York, NY.  Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will present a corporate overview on Monday, September 9, 2024, at 9:00 AM ET.  The presentation can be accessed at https://bit.ly/4coqH9K.2024 Cantor Global Healthcare Conference, which is being held September 17-19, 2024, in New York, NY. Mr. Hughes and Mr. S

Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the commercial royalty and milestone portfolio with the acquisition of economic interests in XACIATO™ (clindamycin phosphate) vaginal gel 2%, and two novel Phase 3 assets, from Daré Bioscience Completed the acquisition of Kinnate Pharmaceuticals, adding several potential royalty streams, as well as more than $9.5 million in non-dilutive capital EMERYVILLE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, reported its second quarter 2024 financial results and highlighted rece

EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company") today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about July 15, 2024, to respec

EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals' recent sale of its Priority Review Voucher (PRV) for $108 million to an undisclosed buyer.  "OJEMDA™ offers patients six months of age and older who have relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG) the only approved therapy studied in and approved specifically for pLGG driven by BRAF fusions," stated Owen Hughes, Chief Executive Officer of XOMA.  "With this milestone in hand, we have more than recouped

Aldoxorubicin Returns to LadRx LadRx Corporation (OTCQB:LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that the Company and NantCell, Inc. ("NantCell"), together with NantCell's parent company ImmunityBio, Inc. ("ImmunityBio"), have agreed to a mutual termination of the license of aldoxorubicin entered into in 2017. With the termination of the license agreement between LadRx and NantCell, LadRx regains control of aldoxorubicin. In 2023, LadRx transferred the royalty and milestone rights of arimoclomol and aldoxorubicin to XOMA Corporation (NASDAQ:XOMA) ("XOMA") in exchange for

The FDA will convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee (GeMDAC) on August 2 to review the marketing application for Zevra Therapeutics Inc.’s (NASDAQ:ZVRA) arimoclomol for Niemann-Pick disease type C (NPC). The application for arimoclomol has been assigned a Prescription Drug User Fee Act (PDUFA) action date of September 21, which was extended from June 21. Previously known as KemPharm, Zevra Therapeutics acquired arimoclomol from Orphazyme for $12.8 million.  In 2021, the FDA issued a complete response letter to arimoclomol as a treatment option for Niemann-Pick disease type C. The CRL asked for additional qualitative and quantitati

In the preceding three months, 5 analysts have released ratings for XOMA (NASDAQ:XOMA), presenting a wide array of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 1 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $67.2, with a high estimate of $74.00 and a low estimate of $40.00. This current average represents a 9.19% decr

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on XOMA (NASDAQ:XOMA) in the last three months. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 1 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $67.2, with a high estimate of $74.00 and a low estimate of $40.00. A decline of 9.19% from the prior

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.

XOMA (NASDAQ:XOMA) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.81) by 6.17 percent. This is a 12.24 percent increase over losses of $(0.98) per share from the same period last year.

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.

Organon, a global women's healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023. XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two additional women's health assets: Ovaprene, an investigational potential first-in-category Phase 3 hormone-free monthly intravaginal contraceptive, and Sildenafil Cream, 3.6%, a potential first-in-category Phase 3-ready candidate for female sexual arousal disorder. Bayer HealthCare holds the exclusive rights to U.S. commercialization of Ovaprene. XOMA provided $22 million upfront as non-dilutive royalty capital solution to Daré Bioscience.

4 analysts have expressed a variety of opinions on XOMA (NASDAQ:XOMA) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 1 0 0 0 0 Analysts have recently evaluated XOMA and provided 12-month price targets. The average target is $65.5, accompanied by a high estimate of $74.00 and a low estimate of $40.00. This current average r

Earned $9 million milestone upon U.S. Food and Drug Administration's approval of Day One's OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital to XOMA's balance sheet Expanded the commercial royalty and milestone portfolio with the acquisitions of economic interests in DSUVIA® (sufentanil sublingual tablet) and XACIATO™ (clindamycin phosphate) vaginal gel 2%, as well as two Phase 3 assets Launched XOMA's first stock repurchase program for up to $50 million EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royal

BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today the Board of Directors has named Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board.  Mr. Hughes has served as XOMA's Executive Chairman and Interim Chief Executive Officer since January 1, 2023. "The rest of the Board and I have been impressed with Owen's leadership over the past year and his vision to establish XOMA as the premiere biotech royalty aggregator.  I am looking forward to working closely with Owen and the team to further accelerate the Company's growth and maximize value for all XOMA stockholders," stated

Chief Executive Officer Jim Neal appointed as Chairman; Former Chairman W. Denman Van Ness to remain Lead Independent Director Company is launching Chief Executive Officer search; Jim Neal will retire from CEO role when successor has been appointed EMERYVILLE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today the appointment of Jim Neal, Chief Executive Officer of XOMA, as Chairman of the Board.  W. Denman (Denny) Van Ness, who has served as XOMA's Chairman of the Board since 2011, will continue as

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that Natasha A. Hernday has joined Alpine’s Board of Directors. Ms. Hernday brings more than 20 years of experience in corporate development and corporate strategy. “I’m delighted to welcome Natasha to Alpine Immune Sciences’ Board at this important moment in our company’s history, as we build on our strategic partnership with AbbVie and leverage Alpine’s financial strength to further advance our development pipeline,” said Mitchell H. Gold, M.D., Executive